TrialAsia-Pacific journal of clinical oncology2019

Phase II APEC trial: The impact of primary tumor side on outcomes of first-line cetuximab plus FOLFOX or FOLFIRI in patients with RAS wild-type metastatic colorectal cancer.

Timothy Price et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.